AN2 Therapeutics (ANTX) Free Cash Flow (2021 - 2026)
AN2 Therapeutics (ANTX) reported Free Cash Flow of -$12.1 million for Q1 2026, down 13.64% year-over-year from -$14.0 million in Q1 2025, and down 130.66% quarter-over-quarter from -$5.2 million in Q4 2025.
AN2 Therapeutics (ANTX) Free Cash Flow (2021 - 2026) Analysis & Trends
AN2 Therapeutics (ANTX) has 6 years of Free Cash Flow data on file, last reported at -$12.1 million in Q1 2026.
- Free Cash Flow for Q1 2026 came in at -$12.1 million, down 13.64% year-over-year; the trailing twelve-month figure through Mar 2026 was -$31.3 million (up 26.02% YoY), and the FY2025 annual result was -$29.8 million, up 39.43% from the prior year.
- Free Cash Flow retreated to -$12.1 million in Q1 2026 per ANTX's latest filing, from -$5.2 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$5.2 million in Q4 2025 and troughed at -$17.6 million in Q1 2024.
- A 5-year average of -$10.5 million and a median of -$10.6 million in 2025 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2022 and 2024: Free Cash Flow tumbled 336.94% in 2022, then surged 69.24% in 2024.
- A 5-year view of Free Cash Flow shows it stood at -$7.6 million in 2022, then tumbled by 123.72% to -$17.1 million in 2023, then surged by 69.24% to -$5.3 million in 2024, then gained by 0.44% to -$5.2 million in 2025, then tumbled by 130.66% to -$12.1 million in 2026.
- Business Quant data shows ANTX's Free Cash Flow at -$12.1 million in Q1 2026, -$5.2 million in Q4 2025, and -$6.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -2.49 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 63,220.27 |
| 10 | AN2 Therapeutics | 161.95 Mn | 161.95 Mn | - | -12.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -12.07 Mn |
| Mar 31, 2026 | -12.07 Mn |
| Dec 31, 2025 | -5.23 Mn |
| Dec 31, 2025 | -5.23 Mn |
| Sep 30, 2025 | -6.40 Mn |
| Sep 30, 2025 | -6.40 Mn |
| Jun 30, 2025 | -7.58 Mn |
| Jun 30, 2025 | -7.58 Mn |
| Mar 31, 2025 | -10.62 Mn |
| Mar 31, 2025 | -10.62 Mn |
| Dec 31, 2024 | -5.26 Mn |
| Dec 31, 2024 | -5.26 Mn |
| Sep 30, 2024 | -12.02 Mn |
| Sep 30, 2024 | -12.02 Mn |
| Jun 30, 2024 | -14.38 Mn |
| Jun 30, 2024 | -14.38 Mn |
| Mar 31, 2024 | -17.59 Mn |
| Mar 31, 2024 | -17.59 Mn |
| Dec 31, 2023 | -17.09 Mn |
| Dec 31, 2023 | -17.09 Mn |